文献速递痛风与晶体性关节病

风湿病学新视角:非布司他与别嘌醇在痛风合并心血管疾病患者中心血管安全性试验及FDA公共安全警示的意义

New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.
PubMed 文献 · Arthritis Rheumatol · 2018-01-01

本文围绕CARES试验及美国FDA公共安全警示展开述评。CARES试验显示,在基线合并心血管疾病的痛风患者中,别嘌醇与非布司他在心血管事件主要复合终点上无显著差异,但非布司他组心血管死亡和全因死亡风险显著升高。作者认为CARES试验不能证明非布司他升高心血管死亡风险,但提示其风险高于别嘌醇,不支持非布司他作为一线降尿酸治疗。

要点

  • CARES试验中别嘌醇与非布司他主要复合心血管终点无显著差异,但非布司他组心血管死亡和全因死亡风险显著升高
  • 作者认为CARES试验不能证明非布司他升高心血管死亡风险,但提示其风险高于别嘌醇
  • FDA安全警示强调痛风患者降尿酸治疗需共享决策并讨论非布司他心血管安全性

核心结论

  • CARES试验不能证明非布司他升高心血管死亡风险,但提示非布司他风险高于别嘌醇。
  • CARES试验结果不支持非布司他作为一线降尿酸治疗,并对其在降尿酸治疗决策树各分支中的定位提出疑问。
  • FDA安全警示强调痛风患者降尿酸治疗需共享医疗决策,包括讨论非布司他的心血管安全性。

研究设计与样本

  • 本文为述评,围绕已发表的CARES试验及美国FDA公共安全警示展开讨论。
  • CARES试验在基线合并确诊心血管疾病的痛风受试者中比较别嘌醇与非布司他。
  • 文中还讨论了其他正在进行的非布司他与别嘌醇对比研究,其结果尚待公布。

主要发现

  • CARES试验显示,别嘌醇与非布司他在心血管事件主要复合终点上无显著差异。
  • CARES试验显示,非布司他组心血管死亡和全因死亡风险显著升高。
  • 痛风患者中心血管合并症常见,降尿酸治疗是痛风长期管理的核心,黄嘌呤氧化还原酶抑制剂治疗是共识一线方案。
  • 别嘌醇通常是首先使用的黄嘌呤氧化还原酶抑制剂,非布司他是有效的黄嘌呤氧化还原酶抑制剂选择,常用于别嘌醇不耐受时。
  • 非布司他的替代方案常包括别嘌醇剂量递增和单用促尿酸排泄治疗或促尿酸排泄治疗联合别嘌醇。

临床怎么用

  • 降尿酸治疗是痛风长期管理的核心,黄嘌呤氧化还原酶抑制剂治疗是共识一线方案。
  • 别嘌醇通常是首先使用的黄嘌呤氧化还原酶抑制剂,非布司他常用于别嘌醇不耐受时。
  • 作者认为CARES试验结果不支持非布司他作为一线降尿酸治疗。
  • 作者指出非布司他的替代方案常包括别嘌醇剂量递增和单用促尿酸排泄治疗或联合别嘌醇。
  • FDA安全警示强调痛风患者降尿酸治疗需共享医疗决策,包括讨论非布司他的心血管安全性。

局限性

  • 本文评估了CARES试验的优势与局限性,并审视了结果的稳健性和生物学合理性。
  • CARES试验不能证明非布司他升高心血管死亡风险,仅提示非布司他风险高于别嘌醇。
  • 其他正在进行的非布司他与别嘌醇对比研究结果尚待公布。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recently, the US Food and Drug Administration (FDA) issued a public safety alert, responding to the results of the now-published Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities (CARES) trial. The CARES trial showed no significant difference between allopurinol and febuxostat in the primary composite end point of cardiovascular (CV) events in subjects with gout and established CV comorbidities at baseline. However, there was a significantly increased risk of CV and all-cause mortality with febuxostat. Urate-lowering therapy (ULT) is central to the long-term management of gout, and xanthine oxidoreductase inhibitor (XOI) therapy is the consensus first-line approach. Allopurinol is generally the first XOI used, but febuxostat is an effective XOI option, and is commonly used when allopurinol is not tolerated. These data are further relevant since CV comorbidities are common in gout. Here, we examine why the CARES trial was done, and discuss other, ongoing comparative studies of febuxostat and allopurinol whose results are awaited. We assess the strengths and limitations of the CARES trial, and appraise the robustness and biologic plausibility of the results. The CARES trial does not prove that febuxostat raises CV mortality risk, but suggests greater risk with febuxostat than allopurinol. The CARES trial results do not support first-line use of febuxostat ULT, and raise questions about febuxostat placement at various pharmacologic ULT decision tree branches. Alternatives to febuxostat that are frequently effective include allopurinol dose escalation and uricosuric therapy alone or combined with allopurinol. The FDA safety alert highlights the need for shared ULT medical decision-making with gout patients, including discussion of the CV safety of febuxostat.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Choi H, Neogi T, Stamp L, et al. New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert. Arthritis Rheumatol. 2018. PMID: 29869840. doi:10.1002/art.40583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。